KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 Shares
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 25,900 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $8.02, for a total value of $207,718.00. Following the completion of the transaction, the insider now directly owns 2,876,027 shares in the company, valued at approximately $23,065,736.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.05, for a total value of $80,500.00.
- On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $7.21, for a total value of $1,273,624.87.
KalVista Pharmaceuticals, Inc. (NASDAQ KALV) traded down 13.11% during trading on Friday, hitting $6.96. The stock had a trading volume of 162,624 shares. The firm’s market cap is $67.60 million. The firm’s 50 day moving average is $8.20 and its 200 day moving average is $7.83. KalVista Pharmaceuticals, Inc. has a 1-year low of $6.09 and a 1-year high of $10.65.
KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative return on equity of 63.41% and a negative net margin of 5,863.31%. The business had revenue of $0.10 million for the quarter. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post ($2.94) earnings per share for the current year.
A number of research analysts recently weighed in on the company. BTIG Research assumed coverage on KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 price objective on the stock. ValuEngine upgraded KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 2nd.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC acquired a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned about 1.01% of KalVista Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 75.66% of the company’s stock.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.